188 related articles for article (PubMed ID: 11324989)
1. Suppressed sympathetic skin response in Parkinson disease.
Haapaniemi TH; Korpelainen JT; Tolonen U; Suominen K; Sotaniemi KA; Myllylä VV
Clin Auton Res; 2000 Dec; 10(6):337-42. PubMed ID: 11324989
[TBL] [Abstract][Full Text] [Related]
2. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
Haapaniemi TH; Kallio MA; Korpelainen JT; Suominen K; Tolonen U; Sotaniemi KA; Myllylä VV
J Neurol; 2000 Nov; 247(11):868-74. PubMed ID: 11151420
[TBL] [Abstract][Full Text] [Related]
3. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
4. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
5. Sympathetic sudomotor and vasoconstrictive neural function in patients with Parkinson's disease.
Shindo K; Iida H; Watanabe H; Ohta E; Nagasaka T; Shiozawa Z
Parkinsonism Relat Disord; 2008 Nov; 14(7):548-52. PubMed ID: 18321756
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of sympathetic skin response in Parkinson's disease.
Schestatsky P; Ehlers JA; Rieder CR; Gomes I
Parkinsonism Relat Disord; 2006 Dec; 12(8):486-91. PubMed ID: 16867313
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early Parkinson's disease: are complicated strategies justified?
Ahlskog JE
Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between homocysteinaemia and sympathetic skin response in Parkinson's disease].
Crespo-Burillo JA; Almarcegui-Lafita C; Dolz-Zaera I; Alarcia-Alejos R; Roche JC; Ara JR; Capablo-Liesa JL
Rev Neurol; 2017 Oct; 65(8):348-352. PubMed ID: 28990644
[TBL] [Abstract][Full Text] [Related]
9. Sympathetic skin response in Parkinson's disease before and after mental stress.
Giza E; Katsarou Z; Georgiadis G; Bostantjopoulou S
Neurophysiol Clin; 2012 Apr; 42(3):125-31. PubMed ID: 22500702
[TBL] [Abstract][Full Text] [Related]
10. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
11. Treating the progressive stages of Parkinson's disease.
Varon J; Jacobs MB
Postgrad Med; 1991 Jul; 90(1):63-6, 69-71. PubMed ID: 1905807
[TBL] [Abstract][Full Text] [Related]
12. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Bhattacharya KF; Nouri S; Olanow CW; Yahr MD; Kaufmann H
Parkinsonism Relat Disord; 2003 Mar; 9(4):221-4. PubMed ID: 12618057
[TBL] [Abstract][Full Text] [Related]
13. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
14. Auditory and inspiratory gasp-evoked sympathetic skin response: age effects.
Hay JE; Taylor PK; Nukada H
J Neurol Sci; 1997 May; 148(1):19-23. PubMed ID: 9125386
[TBL] [Abstract][Full Text] [Related]
15. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
[TBL] [Abstract][Full Text] [Related]
16. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
Ondo W; Warrior D; Overby A; Calmes J; Hendersen N; Olson S; Jankovic J
Arch Neurol; 2000 Oct; 57(10):1464-9. PubMed ID: 11030799
[TBL] [Abstract][Full Text] [Related]
17. Selegiline in the treatment of Parkinson's disease--long term experience.
Yahr MD; Elizan TS; Moros D
Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
[TBL] [Abstract][Full Text] [Related]
18. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
19. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
